1. Market Research
  2. > Healthcare Market Trends

Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

  • April 2017
  • 658 pages
  • Currentpartnering
Report ID: 3679174

Summary

Table of Contents

Search Inside

Summary
The Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies

Description
The Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in biomarker partnering deals
- Biomarker partnering agreement structure
- Biomarker partnering contract documents
- Top biomarker deals by value
- Most active biomarker dealmakers

The Global Biomarker Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Biomarker agreements announced in the healthcare sectors.

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 1,000 online deals records of actual biomarker deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Biomarker partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual Biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of Biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biomarker dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Biomarker deals since 2010. Deals are listed by headline value, signed by big pharma, most active Biomarker dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biomarker dealmaking with a brief summary followed by a comprehensive listing of Biomarker deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2010. The chapter is organized by specific Biomarker technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Biomarker partnering company A-Z, deal type definitions and Biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biomarker partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biomarker technologies and products.

Key benefits

Global Biomarker Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:
- In-depth understanding of biomarker deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of biomarker agreements with numerous real life case studies
- Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies
- Access to most active biomarker dealmakers since 2010
- Insight into the terms included in a biomarker agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope
Global Biomarker Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:
- Trends in biomarker dealmaking in the biopharma industry since 2010
- Analysis of biomarker deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life biomarker deals
- Access to biomarker contract documents
- The leading biomarker deals by value since 2010
- Most active biomarker dealmakers since 2010
- The leading biomarker partnering resources

In Global Biomarker Partnering 2010-2017: Deal trends, players, financials and forecasts, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Biomarker Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,000 biomarker deals.

Analyzing actual contract agreements allows assessment of the following:
- What are the precise biomarker rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Global Biomarker Partnering 2010-2017 provides the reader with the following key benefits:
- In-depth understanding of biomarker deal trends since 2010
- Analysis of the structure of biomarker agreements with numerous real life case studies
- Comprehensive access to over 1,000 actual biomarker deals entered into by the world’s biopharma companies, together with real world clause examples
- Access to headline, upfront, milestone and royalty data
- Full listing of biomarker deals by company A-Z, deal value, phase of development, deal type, and therapy focus
- Identify leading biomarker deals by value since 2010
- Identify the most active biomarker dealmakers since 2010
- Detailed access to actual biomarker deals and contracts enter into by the leading fifty big pharma companies
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Infectious Disease Testing Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 59500
  • Industry report
  • May 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

Virology and Bacteriology Testing Market 2021: A 68-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 59500
  • Industry report
  • June 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

Automated Microbiology Market 2021: A 68-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification

  • $ 52500
  • Industry report
  • June 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides granular data and analysis not available from any other published source. The survey is designed to help current suppliers and potential market ...


Download Unlimited Documents from Trusted Public Sources

Hospital Industry in the UK

  • August 2017
    31 pages
  • Hospital  

  • United Kingdom  

View report >

Hospital Industry in the UK

  • August 2017
    192 pages
  • Hospital  

    Diabetes  

    Type 2 Diabetes  

  • United Kingdom  

View report >

Infectious Disease Statistics

  • August 2017
    188 pages
  • Infectious Dise...  

  • United States  

    Europe  

    Africa  

View report >

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.